OMAHA, Neb. — The University of Nebraska’s medical school is seeking 25 people for a study of a medication derived from marijuana.
The University of Nebraska Medical Center in Omaha says the study will investigate the use of cannabidiol (CBD) in patients with drug-resistant epilepsy who also will take anti-epileptic drugs.
SPECIAL REPORT: CBD in Colorado. Learn about the cannabis plant compound cannabidiol, which has drawn hundreds of desperate families to Colorado, in This Denver Post series that was a 2015 Pulitzer finalist
Subscribe to The Cannabist’s newsletter here.
Cannabidiol is extracted from the marijuana plant — Cannabis sativa — and is distinct from the component that makes people high.
The study medication is called Epidiolex. It’s described as a plant-based pharmaceutical formulation of pure cannabidiol and contains only trace amounts of the psychoactive component of cannabis, tetrahydrocannabinol (THC).
The study is authorized under a legislative bill approved in 2015.